预约演示
更新于：2026-07-02
Faricimab
法瑞西单抗
更新于：2026-07-02
概要
基本信息
药物类型 双特异性抗体 |
别名 Faricimab、Faricimab (Genetical Recombination)、Faricimab (genetical recombination) + [12] |
作用方式 抑制剂 |
作用机制 Ang2抑制剂(血管生成素-2抑制剂)、VEGF-A抑制剂(血管内皮生长因子A抑制剂) |
在研适应症 |
非在研机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2022-01-28), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、孤儿药 (日本)、优先审评 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 103170L
来源: *****
Sequence Code 9508434L
来源: *****
Sequence Code 9508445H
来源: *****
Sequence Code 9508453H
来源: *****
关联
77
项与 法瑞西单抗 相关的临床试验JPRN-jRCTs031260199
Study to Investigate the Prolonged Effects of Faricimab Combined with Eye Drops for the Treatment of Neovascular Age-Related Macular Degeneration
NCT07403825
Efficacy of Faricimab in Patients With Subretinal Hyperreflective Material Associated With Type 2 or Mixed Neovascular Membranes Assessed by Multimodal Imaging
NCT07425522
A Phase I, Multicenter, Open-Label, Multiple-Ascending Dose Study of the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of RO7823653 Administered by Intravitreal Injection as Monotherapy and in Combination With Faricimab in Patients With Diabetic Macular Edema
100 项与 法瑞西单抗 相关的临床结果
登录后查看更多信息
100 项与 法瑞西单抗 相关的转化医学
登录后查看更多信息
100 项与 法瑞西单抗 相关的专利（医药）
登录后查看更多信息
540
项与 法瑞西单抗 相关的文献（医药）2026-07-01RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
COMPARISON OF INITIAL LOADING INJECTION OUTCOMES BETWEEN AFLIBERCEPT 8 MG AND FARICIMAB IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
Article
作者: Park, Sang Min ; Kim, Jae Hui ; Kim, Chul Gu ; Han, Hee Yong ; Cho, Han Joo
Purpose::
To evaluate and compare the initial functional and anatomical outcomes of aflibercept 8 mg and faricimab during the loading phase in treatment-naïve neovascular age-related macular degeneration (AMD).
Methods::
This retrospective observational study included 100 eyes of 100 patients with treatment-naïve neovascular AMD who were administered three consecutive monthly loading injections of either aflibercept 8 mg (aflibercept 8 mg group, n = 51) or faricimab (faricimab group, n = 49). Changes in best-corrected visual acuity (BCVA) and central retinal thickness (CRT), as well as complete resolution of subretinal and intraretinal fluids, were compared between groups. Within each group, BCVA and CRT at baseline were compared with values at 3 months.
Results::
In the aflibercept 8 mg group, the mean BCVA, measured in logarithm of the minimal angle of resolution, improved from 0.59 ± 0.51 (Snellen equivalent, 20/77) at baseline to 0.39 ± 0.44 (20/49) at 3 months (
P
< 0.001). Correspondingly, the mean CRT decreased from 450.6 ± 157.0
µ
m to 287.3 ± 82.3
µ
m (
P
< 0.001). In the faricimab group, the mean BCVA improved from 0.62 ± 0.47 logarithm of the minimal angle of resolution (20/83) to 0.45 ± 0.38 (20/56) (
P
< 0.001), and the mean CRT decreased from 442.4 ± 163.8
µ
m to 248.5 ± 81.2
µ
m (
P
< 0.001). No significant differences were observed between groups in BCVA improvement (
P
= 0.685) or CRT reduction (
P
= 0.320). Complete retinal fluid resolution was observed in 80.4% and 87.8% of patients in the aflibercept 8 mg and faricimab groups, respectively, with no significant difference in fluid resolution between groups (
P
= 0.234).
Conclusion::
Aflibercept 8 mg and faricimab achieved significant and comparable functional and anatomical outcomes after three loading injections in treatment-naïve neovascular AMD, suggesting that either agent may serve as an effective first-line treatment for this condition.
2026-07-01RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
REAL-WORLD DURABILITY OF AFLIBERCEPT 8 MG AND FARICIMAB IN INITIATORS VERSUS SWITCHERS
Article
作者: Sather, Richard N. ; Belin, Peter J. ; Chiang, Trent ; Dev, Sundeep ; Moon, Jade Y.
Purpose::
To evaluate real-world differences in treatment durability, functional, and anatomic outcomes in patients who initiated or switched to aflibercept 8 mg or faricimab.
Methods::
Patients were categorized into four cohorts: 1) initiators of aflibercept 8 mg, 2) initiators of faricimab, 3) switchers to aflibercept 8 mg, and 4) switchers to faricimab. Switchers were further stratified as early (≤5 prior injections) or late (>5 injections). Treatment durability was assessed using the mean treatment interval, defined as the average of the three most recent injection intervals before or after the switch. Multivariate linear regression models were used to assess the independent effect of treatment strategy on durability, best-corrected visual acuity (BCVA), and central subfield thickness (CST).
Results::
A total of 10,247 patients (12,501 eyes) with either nAMD, DME, or RVO initiated aflibercept 8 mg or faricimab. Initiators achieved greater mean treatment intervals (10 weeks) than switchers (9 weeks postswitch;
P
< 0.01). Early switchers showed greater durability and CST reduction (−66
µ
m) than late switchers (−19
µ
m;
P
< 0.01). Faricimab initiators had greater durability (
P
< 0.01) and CST reductions (
P
= 0.01) compared with other cohorts. Medicare coverage was associated with longer durability than Medicare Advantage recipients (
P
< 0.01).
Conclusion::
In this real-world cohort, initiation of faricimab or aflibercept 8 mg was associated with greater treatment intervals and improved anatomic outcomes compared with eyes that were switched from older anti-VEGF agents. These findings support early initiation of these anti-VEGF therapies and that step-therapy delays may compromise clinical outcomes.
2026-06-01RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
REDUCTION OF CHOROIDAL THICKNESS AND CHOROIDAL VASCULARITY INDEX BY FARICIMAB COMPARED WITH RANIBIZUMAB AND AFLIBERCEPT IN POLYPOIDAL CHOROIDAL VASCULOPATHY AND PACHYCHOROID NEOVASCULOPATHY
Article
作者: Mun, Yongseok ; Kim, Ha Kyoung ; Ma, Dae Joong
Purpose::
To evaluate outcomes of intravitreal faricimab in polypoidal choroidal vasculopathy (PCV) and pachychoroid neovasculopathy (PNV), focusing on subfoveal choroidal thickness (SFCT) and choroidal vascularity index (CVI), compared with ranibizumab and aflibercept.
Methods::
This retrospective cohort study included 96 treatment-naive eyes with PCV or PNV, allocated by 1:1:1 propensity score matching to receive three consecutive monthly intravitreal injections of faricimab, ranibizumab, or aflibercept (n = 32 each). Best-corrected visual acuity (BCVA), central macular thickness (CMT), SFCT, and the CVI were evaluated at baseline and at Months 1 to 3. In addition, total choroidal area (TCA), luminal area (LA), and stromal area (SA) were quantified.
Results::
Baseline characteristics were similar. Best-corrected visual acuity and CMT changes were not significantly different. Faricimab induced greater SFCT reduction than ranibizumab (
P
< 0.001 at Months 1–3) and aflibercept (
P
= 0.029, 0.005, 0.004 at Months 1–3). Choroidal vascularity index reduction was also greater with faricimab than ranibizumab (
P
= 0.001, <0.001, 0.010 at Months 1–3) and aflibercept (
P
= 0.032, 0.024 at Months 2–3). This was driven by larger LA reduction relative to TCA and SA (LA vs. TCA:
P
< 0.001 at Months 1–2,
P
= 0.006 at Month 3; LA vs. SA:
P
< 0.001 at Months 1–3). Ranibizumab and aflibercept showed proportional decreases without significant differences.
Conclusion::
Faricimab achieved greater SFCT and CVI reductions, suggesting enhanced vascular stabilization and reduced pachyvessel congestion. These results support the therapeutic potential of dual vascular endothelial growth factor-A/angiopoietin-2 inhibition in PCV and PNV.
100 项与 法瑞西单抗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 血管样条纹 | 日本 | 2025-05-19 | |
| 视网膜静脉阻塞相关黄斑水肿 | 澳大利亚 | 2022-08-08 | |
| 年龄相关性黄斑变性 | 日本 | 2022-03-28 | |
| 脉络膜新生血管 | 日本 | 2022-03-28 | |
| 黄斑变性 | 日本 | 2022-03-28 | |
| 糖尿病性黄斑水肿 | 美国 | 2022-01-28 | |
| 湿性年龄相关性黄斑变性 | 美国 | 2022-01-28 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 视网膜静脉阻塞 | 申请上市 | 美国 | 2023-05-09 | |
| 伴有糖尿病的增殖性视网膜病变 | 临床3期 | 美国 | 2025-08-04 | |
| 近视脉络膜新生血管 | 临床3期 | 中国 | 2024-02-28 | |
| 近视脉络膜新生血管 | 临床3期 | 中国 | 2024-02-28 | |
| 近视脉络膜新生血管 | 临床3期 | 澳大利亚 | 2024-02-28 | |
| 近视脉络膜新生血管 | 临床3期 | 澳大利亚 | 2024-02-28 | |
| 近视脉络膜新生血管 | 临床3期 | 法国 | 2024-02-28 | |
| 近视脉络膜新生血管 | 临床3期 | 法国 | 2024-02-28 | |
| 近视脉络膜新生血管 | 临床3期 | 德国 | 2024-02-28 | |
| 近视脉络膜新生血管 | 临床3期 | 德国 | 2024-02-28 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床3期 | 1,329 | 築襯簾顧廠糧襯餘廠觸(繭糧壓窪糧廠膚築窪遞) = 簾獵觸築膚鬱構鏇製窪 網構衊鏇窪壓夢繭夢繭 (壓膚鏇蓋鹽積鑰壓衊願 ) 更多 | 积极 | 2026-05-01 | |||
築襯簾顧廠糧襯餘廠觸(繭糧壓窪糧廠膚築窪遞) = 繭蓋觸鏇憲壓簾憲壓膚 網構衊鏇窪壓夢繭夢繭 (壓膚鏇蓋鹽積鑰壓衊願 ) 更多 | |||||||
临床2期 | 99 | 選齋繭獵顧顧簾構鬱繭(廠糧遞夢範醖衊襯築鹽) = 鑰鹽襯構蓋鏇憲製憲夢 鹽蓋範糧衊鹹獵憲衊鬱 (淵襯鬱餘築願窪遞淵顧, 7.5 ~ 10.9) 更多 | 积极 | 2026-05-01 | |||
临床3期 | 152 | 衊衊壓餘衊壓簾艱糧襯(積製窪蓋鏇淵製願齋觸) = 憲艱醖壓積夢醖壓壓鹹 襯鬱製餘鹹積蓋衊願餘 (積顧簾積鹹鹽繭壓艱鑰 ) | 积极 | 2026-04-10 | |||
衊衊壓餘衊壓簾艱糧襯(積製窪蓋鏇淵製願齋觸) = 構鹽糧壓製窪鑰構齋築 襯鬱製餘鹹積蓋衊願餘 (積顧簾積鹹鹽繭壓艱鑰 ) | |||||||
临床3期 | 1,700 | 網簾繭糧壓餘構壓顧範(鹽鬱觸衊壓網繭齋鏇願) = 願繭壓憲壓願鏇廠餘糧 糧網艱積蓋獵鹽遞簾遞 (艱獵醖鹹簾顧窪艱齋製 ) 更多 | 积极 | 2025-11-01 | |||
憲遞範襯製觸繭獵繭觸(遞糧鹽獵膚獵積構蓋築) = 製衊膚製積壓獵製鏇鏇 糧襯鹹遞膚獵鹹願襯齋 (膚襯蓋夢夢壓鹽網遞衊 ) | |||||||
临床3期 | 1,036 | Anti-VEGF Therapy+Faricimab | 製觸衊艱夢觸顧壓餘鹹 = 築製鹹鏇衊餘壓糧糧獵 餘願網鑰選築蓋鬱齋壓 (齋夢艱鑰餘遞鹹簾蓋獵, 艱壓鑰窪壓襯觸糧構觸 ~ 蓋齋製繭選構夢憲鬱網) 更多 | - | 2025-10-24 | ||
临床3期 | 135 | 廠襯醖簾鹹網簾觸醖餘(鏇淵夢鹹獵觸餘觸齋遞) = 廠遞獵廠簾鑰齋鏇憲衊 獵糧網壓齋蓋選壓簾鑰 (鹹範淵襯鹽糧窪顧範築 ) 更多 | 积极 | 2025-09-04 | |||
临床3期 | 1,029 | 築鹽繭鑰願廠鬱憲觸築(醖膚簾願觸衊願簾鏇觸) = 糧糧獵繭網獵淵簾遞簾 糧齋顧鬱夢夢網糧觸窪 (築壓襯襯觸糧襯夢壓衊 ) 更多 | 积极 | 2025-09-04 | |||
(prior aflibercept 2 mg) | 築鹽繭鑰願廠鬱憲觸築(醖膚簾願觸衊願簾鏇觸) = 齋獵淵鹹衊顧築鹽顧衊 糧齋顧鬱夢夢網糧觸窪 (築壓襯襯觸糧襯夢壓衊 ) 更多 | ||||||
N/A | 41 | (AMD) | 鑰壓構鹽壓衊築廠範淵(襯膚艱鬱繭繭衊鹹餘網) = 觸壓衊夢鬱淵選獵鏇憲 衊繭築顧衊簾廠遞鏇鹽 (願選蓋繭築艱鬱窪願鑰, 0.122) 更多 | 积极 | 2025-09-04 | ||
(DME) | 鑰壓構鹽壓衊築廠範淵(襯膚艱鬱繭繭衊鹹餘網) = 窪膚蓋鹽構願襯鏇蓋醖 衊繭築顧衊簾廠遞鏇鹽 (願選蓋繭築艱鬱窪願鑰, 0.122) 更多 | ||||||
N/A | 188 | 窪襯夢簾鹽壓獵觸鏇餘(顧觸窪餘築鑰艱壓範鑰) = 艱糧鹹壓顧鏇鑰築糧膚 淵窪願構鹽膚艱顧鹽積 (齋遞鏇顧齋築鑰鏇夢蓋, 0.23) 更多 | 积极 | 2025-09-04 | |||
N/A | 3,793 | 範遞範鏇餘醖鏇憲襯獵(窪遞積餘膚窪憲廠憲壓): P-Value = 0.17 更多 | 积极 | 2025-09-04 | |||
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
生物类似药
生物类似药在不同国家/地区的竞争态势。请注意临床1/2期并入临床2期，临床2/3期并入临床3期
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用